ICB therapy in the blood cancer setting is relatively new and although dozens of clinical trials are ongoing and actively recruiting [47], no large-scale study has been completed evaluating the efficacy of anti-PD1 therapies in AML. Here, PDCD1 is linked to acute myeloid leukemia.